Stephens Inc Cerus Corp Transaction History

Stephens Inc

  • $7.43 Billion
  • Q3 2025

A detailed history of Stephens Inc transactions in Cerus Corp stock. As of the latest transaction made, Stephens Inc holds 98,491 shares of CERS stock, worth $159,555. This represents 0.0% of its overall portfolio holdings.

Number of Shares
98,491
Previous 110,294 10.7%
Holding current value
$159,555
Previous $155,000 0.65%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 27, 2025
SELL
$1.16 - $1.6 $13,691 - $18,884
-11,803 Reduced 10.7%
98,491 $156,000
Q2 2025

Jul 29, 2025
BUY
$1.22 - $1.51 $10,870 - $13,454
8,910 Added 8.79%
110,294 $155,000
Q1 2025

May 01, 2025
SELL
$1.39 - $2.15 $507 - $784
-365 Reduced 0.36%
101,384 $140,000
Q4 2024

Jan 28, 2025
BUY
$1.52 - $2.03 $5,441 - $7,267
3,580 Added 3.65%
101,749 $156,000
Q3 2024

Oct 28, 2024
SELL
$1.7 - $2.39 $25,134 - $35,336
-14,785 Reduced 13.09%
98,169 $170,000
Q2 2024

Aug 06, 2024
SELL
$1.62 - $2.04 $5,184 - $6,528
-3,200 Reduced 2.75%
112,954 $198,000
Q1 2024

May 15, 2024
SELL
$1.66 - $2.42 $75,820 - $110,533
-45,675 Reduced 28.22%
116,154 $219,000
Q4 2023

Feb 13, 2024
SELL
$1.25 - $2.35 $134,936 - $253,680
-107,949 Reduced 40.01%
161,829 $349,000
Q3 2023

Nov 14, 2023
BUY
$1.5 - $3.07 $19,258 - $39,415
12,839 Added 5.0%
269,778 $437,000
Q2 2023

Aug 14, 2023
SELL
$1.79 - $2.9 $20,209 - $32,741
-11,290 Reduced 4.21%
256,939 $632,000
Q1 2023

May 15, 2023
SELL
$2.65 - $3.81 $970,313 - $1.4 Million
-366,156 Reduced 57.72%
268,229 $796,000
Q4 2022

Jan 25, 2023
SELL
$3.38 - $4.22 $57,493 - $71,782
-17,010 Reduced 2.61%
634,385 $2.32 Million
Q3 2022

Nov 02, 2022
SELL
$3.43 - $5.83 $35,329 - $60,049
-10,300 Reduced 1.56%
651,395 $2.35 Million
Q2 2022

Aug 03, 2022
BUY
$4.41 - $5.69 $18,411 - $23,755
4,175 Added 0.63%
661,695 $3.5 Million
Q1 2022

May 04, 2022
SELL
$4.81 - $6.99 $15,560 - $22,612
-3,235 Reduced 0.49%
657,520 $3.61 Million
Q4 2021

Mar 07, 2022
BUY
$5.97 - $7.93 $78,236 - $103,922
13,105 Added 2.02%
660,755 $4.5 Million
Q3 2021

Oct 27, 2021
BUY
$4.79 - $6.68 $99,392 - $138,610
20,750 Added 3.31%
647,650 $3.94 Million
Q2 2021

Aug 12, 2021
BUY
$5.35 - $6.35 $238,369 - $282,924
44,555 Added 7.65%
626,900 $3.71 Million
Q1 2021

May 14, 2021
BUY
$5.68 - $7.87 $430,055 - $595,869
75,714 Added 14.94%
582,345 $3.5 Million
Q4 2020

Feb 10, 2021
SELL
$5.25 - $8.56 $290,193 - $473,154
-55,275 Reduced 9.84%
506,631 $3.51 Million
Q3 2020

Nov 13, 2020
SELL
$5.78 - $7.47 $1.42 Million - $1.83 Million
-245,491 Reduced 30.41%
561,906 $3.52 Million
Q2 2020

Aug 24, 2020
SELL
$4.5 - $7.02 $346,914 - $541,185
-77,092 Reduced 8.72%
807,397 $5.33 Million
Q1 2020

May 14, 2020
SELL
$2.87 - $5.49 $71,907 - $137,551
-25,055 Reduced 2.75%
884,489 $4.11 Million
Q4 2019

Feb 14, 2020
SELL
$3.84 - $4.86 $116,843 - $147,880
-30,428 Reduced 3.24%
909,544 $3.84 Million
Q3 2019

Oct 18, 2019
BUY
$4.86 - $6.05 $148,968 - $185,444
30,652 Added 3.37%
939,972 $4.85 Million
Q2 2019

Aug 01, 2019
BUY
$4.51 - $6.6 $639,098 - $935,266
141,707 Added 18.46%
909,320 $5.11 Million
Q1 2019

May 03, 2019
BUY
$5.16 - $6.85 $166,471 - $220,994
32,262 Added 4.39%
767,613 $4.78 Million
Q4 2018

Feb 11, 2019
BUY
$4.89 - $7.16 $397,439 - $581,936
81,276 Added 12.43%
735,351 $3.73 Million
Q3 2018

Nov 14, 2018
BUY
$6.89 - $7.78 $4.51 Million - $5.09 Million
654,075 New
654,075 $4.72 Million
Q3 2017

Nov 08, 2017
SELL
$2.22 - $2.73 $2.14 Million - $2.63 Million
-963,702 Closed
0 $0
Q2 2017

Aug 10, 2017
BUY
N/A
963,702
963,702 $2.42 Million

Others Institutions Holding CERS

# of Institutions
166
Shares Held
135M
Call Options Held
126K
Put Options Held
30.1K
View Full List

About CERUS CORP

CERS Quotes by TradingView
  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $287M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Stephens Inc Portfolio

Follow Stephens Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email